Lineage Cell Therapeutics, Inc. (LCTX) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals. Positives include potential $37 million milestone payment from OpRegen, new manufacturing processes, and strategic partnerships. However, the significant net loss, unclear management responses, and reliance on future funding present risks. The Q&A highlights potential expansion with the CIRM grant and partnership strategies, but uncertainties remain. Overall, the sentiment is balanced, leading to a neutral stock price prediction.
Key Financial Performance
Revenue Total revenues were $3.7 million, a decrease of approximately $0.1 million as compared to $3.8 million for the same period in 2024. The decrease is primarily driven by lower royalty revenue and other service revenues recognized of $0.3 million, partially offset by more collaboration revenues of $0.2 million.
Operating Expenses Total operating expenses for the third quarter were $7.5 million, a decrease of $0.1 million as compared to $7.6 million for the same period in 2024.
R&D Expenses R&D expenses were $3.3 million, an increase of $0.1 million as compared to $3.2 million for the same period in 2024. The net increase was primarily driven by $0.2 million for our OPC1 program, $0.4 million for our preclinical programs and other undisclosed programs, partially offset by $0.5 million for our OpRegen program.
G&A Expenses G&A expenses were $4.2 million, a decrease of $0.2 million as compared to $4.4 million for the same period in 2024. This decrease is primarily attributable to stock-based compensation expenses and services provided by third parties.
Loss from Operations Loss from operations was $3.8 million, which was in line with the comparative prior period loss.
Other Income/Expenses Other income expenses reflected other expenses of $26 million compared to other income of $0.8 million for the same period in 2024. The change was largely attributable to the noncash quarterly fair value remeasurement of the warrant liabilities of $26.6 million compared -- primarily due to change in our share prices as compared to the prior year and $0.2 million for exchange rate fluctuations related to Lineage's international subsidiaries.
Net Loss The net loss was $29.8 million or $0.13 per share compared to a net loss of $3 million or $0.02 per share for the same period in 2024. The change was primarily driven by the aforementioned warrant liability.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
OpRegen: Genentech has expanded the clinical sites for the Phase IIa GAlette study to 15 locations, a significant increase from the previous year. Positive clinical outcomes, including improvements in retinal structure and visual acuity, have been reported. Genentech is also evaluating next-generation delivery devices for the program.
ReSonance: Lineage entered a partnership with William Demant Invest A/S (WDI) to fund up to $12 million for preclinical development of ReSonance, a cell transplant program for hearing loss. The program demonstrated the company's ability to develop new cell-based products efficiently.
Islet Cell Initiative: Lineage is working on scaling production of islet cells for Type 1 Diabetes treatment. Early work suggests potential for significant production scale improvements, which could address commercial viability challenges.
Partnership with WDI: The collaboration with WDI provides funding and access to expertise in hearing healthcare, showcasing Lineage's ability to attract external funding for its programs.
OpRegen Commercial Potential: The program's advancements and Roche/Genentech's continued support highlight its potential in the market for dry AMD treatment.
Manufacturing Innovations: Lineage has developed a high-scale GMP banking system and is leveraging it to expand its pipeline efficiently.
Financial Management: The company reported a cash position of $40.5 million, extending its operational runway into Q2 2027. It is also pursuing non-dilutive funding sources like grants and milestone payments.
Pipeline Expansion: Lineage is focusing on expanding its cell therapy platform by developing new assets and leveraging its manufacturing capabilities.
Type 1 Diabetes Initiative: The company is exploring the feasibility of a cell therapy program for Type 1 Diabetes, with a decision expected next quarter.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Clinical Trial Risks: The company does not have full visibility into the GAlette study enrollment or findings, which introduces uncertainty about the outcomes and progress of the OpRegen program. Additionally, the ultimate decision to advance the program lies solely with partners Roche and Genentech, which could delay or halt progress.
Competitive Pressures: The company faces competition from other entities developing their own versions of RPE suspension, including a multinational pharmaceutical company, which could impact the commercial potential of OpRegen.
Manufacturing and Scalability Challenges: The production scale for islet cells, particularly for Type 1 Diabetes, remains a significant challenge. Current differentiation processes yield insufficient quantities of islet cells, which could hinder commercial viability.
Funding and Financial Risks: The company is reliant on external funding sources such as grants, partnerships, and milestone payments. Any delays or failures in securing these funds could impact operations and strategic initiatives.
Economic and Market Conditions: The company’s financial results are influenced by market conditions, including share price fluctuations, which have led to significant noncash quarterly fair value remeasurements of warrant liabilities.
Strategic Execution Risks: The company’s ability to manage a larger portfolio of cell therapy assets while maintaining focus and fiscal discipline is a potential risk. Expanding the pipeline without losing focus or requiring excessive capital investment is a challenge.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
OpRegen Program: Genentech has expanded the number of clinical sites for the Phase IIa GAlette study, with 8 new sites opened in the past 6 months, totaling 15 locations. This acceleration is seen as a positive signal for the program's future. Genentech is also evaluating next-generation delivery devices for OpRegen, which could improve safety and provide a competitive advantage. The program may advance into a controlled clinical trial, with potential surgical optimizations.
ReSonance Program: Lineage entered a partnership with William Demant Invest A/S (WDI) to fund up to $12 million for preclinical development of ReSonance, a cell transplant program for hearing loss. This collaboration demonstrates the company's ability to develop new cell-based products efficiently.
Islet Cell Initiative: Lineage is working on overcoming production scale limitations for islet cell transplants for Type 1 Diabetes. Early work suggests potential for significant production scale improvements, with a feasibility decision expected next quarter. Success could accelerate partnership opportunities.
CIRM CLIN2 Grant: Lineage is a finalist for a CIRM CLIN2 grant, which could provide up to $7 million in funding for the OPC1 spinal cord injury study. A decision is expected by December 11, 2025.
Platform Expansion: Lineage is leveraging its manufacturing platform to expand its pipeline, focusing on scalable and efficient cell therapy development. The company is exploring new cell types and expects to disclose its next indication by the next quarterly call.
Financial Guidance: Lineage's cash position of $40.5 million is expected to support operations into Q2 2027. Additional funding sources include potential CIRM grants, milestone payments from Roche-Genentech, and warrant capital of approximately $37 million if OpRegen advances into a comparator trial.
Market Trends and Growth: The company anticipates a more favorable biotech market in 2026, improving the cost of capital and supporting platform expansion. Lineage expects momentum from the second half of 2025 to continue into 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the internal considerations for the islet cell program's go/no-go decision?
A:The islet cell program faces a biological ceiling in differentiation protocols, limiting scale. Efforts are focused on maximizing the earliest steps of the process to achieve commercially viable output. The goal is to demonstrate the platform's capability to scale, even if not fully realized initially, and to attract potential partnerships.
Q:What is the company's approach to partnerships, including the William Demant collaboration?
A:The company seeks partnerships that are fit for purpose, like the William Demant collaboration for hearing expertise. They aim to balance retaining assets and partnering based on cost, risk, and value creation. Decisions depend on factors like cost of capital and share price, with the goal of maximizing value creation per share.
Q:Can OPC1 be administered at multiple sites along the spinal cord?
A:Yes, OPC1 can be administered at multiple sites during the same surgery. The company is exploring the potential benefits of redosing and multiple doses, supported by a strong safety profile for OPC1.
Q:How might the CIRM grant impact the program?
A:The CIRM grant, potentially over $7 million, would enable the company to expand sites, recruit more patients, and offset trial costs. The funding would be reimbursed over a multiyear period, freeing up cash for other uses.
Q:Are Roche milestones included in the cash runway?
A:No, Roche milestones are not included in the cash runway. Updates will be provided when milestones are achieved.
Q:Could Lineage become a tool or cell services company?
A:The company does not intend to become a tool or cell services company due to challenges in pricing development and unattractive margins. They prefer partnerships that provide significant ownership in the upside and focus on innovation.
Q:What is the process for introducing the new OPC formulation into the dose study?
A:The company plans to introduce the new OPC formulation at the end of the dose study, potentially avoiding a separate bridging study. They are preparing a package for FDA engagement to determine the exact path forward.
Q:What is the status of the dose study and patient recruitment?
A:The dose study has a staggered patient enrollment process, with approximately a month between patients. The company is waiting for CIRM funding to expand sites and accelerate recruitment.
Q:What is the follow-up required for the OpRegen program before moving to a pivotal trial?
A:The primary and secondary assessments occur within 90 days, with longer-term functional data collected over years. The program focuses on surgical optimization rather than prespecified endpoints.
Q:What are the capabilities of the new devices for the OpRegen program?
A:The new devices allow access to the subretinal space via transvitreal or suprachoroidal methods. Each method has trade-offs, and the company is waiting for data from Roche to determine which is superior.
Q:What happens if the company does not receive the CIRM grant?
A:The program will continue without the CIRM grant, but the company would regret missing the external funding opportunity. The cash runway does not include CIRM dollars, so there would be no immediate financial impact.
Q:What is the company's strategy for the OpRegen program and its partnership with Roche?
A:The company trusts Roche's expertise in ophthalmology and believes the asset is in capable hands. They expect Roche to balance optimization with aggressive development, potentially increasing the product's peak sales and success probability.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the following: 1) The exact data package Roche is working toward for the OpRegen program. 2) The timeline and specifics of when and where Roche might present GAlette data. 3) The FDA's stance on introducing the new OPC formulation into the dose study. 4) The stability of the first chronic patient in the dose study prior to dosing. 5) The company's plans if the CIRM grant is not awarded, beyond general assurances of program continuation.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CIRM
GA decrease
GAlette study
Genentech site
Lineage
OpRegen program
OpRegen success
Roche Genentech
Type Diabetes
WDI
advancement
amount
body
cell line
cell pluripotent
cell transplant
cell type
cure Type
decrease period
dozen
effort
evidence OpRegen
grant
initiative
islet cell
obstacle
platform
pluripotent cell
product candidate
production
program OpRegen
revenue
scale
success cell
technology
work
LCTX Transcript
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript
Unknown5-12
The earnings call presents mixed signals. While there are positive aspects such as increased revenue expectations from OpRegen, potential partnerships, and optimism in the cell therapy market, there are concerns about rising expenses and net loss, as well as lack of specific data insights from ongoing studies. The Q&A reveals cautious optimism but also highlights uncertainties, particularly in data availability and competitive positioning. These factors balance each other out, suggesting a neutral impact on stock price.
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript
Positive3-5
The earnings call indicates strong revenue growth, improved margins, and a significant reduction in net loss, showcasing operational efficiencies. The company's strategic initiatives in cell therapy, particularly the OpRegen program, along with optimistic market trends, signal positive future prospects. Despite the absence of shareholder return discussions, the financial health and strategic outlook suggest a positive sentiment. The lack of negative sentiment in the Q&A further supports a positive rating, with expectations of a stock price increase in the 2% to 8% range.
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call reveals mixed signals. Positives include potential $37 million milestone payment from OpRegen, new manufacturing processes, and strategic partnerships. However, the significant net loss, unclear management responses, and reliance on future funding present risks. The Q&A highlights potential expansion with the CIRM grant and partnership strategies, but uncertainties remain. Overall, the sentiment is balanced, leading to a neutral stock price prediction.
Lineage Cell Therapeutics, Inc. (LCTX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Prepared Remarks Transcript
Neutral9-13
LCTX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
